• Gan To Kagaku Ryoho · Sep 2018

    [Regorafenib and Trifluridine and Tipiracil Hydrochloride Can Potentially Improve the Survival Time for Patients with Advanced or Recurrent Colorectal Cancer].

    • Masataka Oki, Akira Nakamura, Naoya Shinamura, Toshikazu Sugaya, Katsuhiko Takagi, and Makoto Sugaya.
    • Dept. of Pharmacy, Asahi General Hospital.
    • Gan To Kagaku Ryoho. 2018 Sep 1; 45 (9): 1297-1303.

    AbstractRegorafenib and trifluridine and tipiracil hydrochloride(TFTD)have been recently used for the treatment of advanced or recurrent colorectal cancer during or after the third-line therapy. These drugs are expected to prolong survival. The progression- free survival period associated with each drug in clinical trials is known to be less than 2 months. However, reports on the overall survival in the sequential therapy with these drugs have been limited. In our institution, sequential therapy using regorafenib and TFTD has achieved longer median survival time(MST)than the previously reported. The MST with monotherapy and sequential therapy was 37 and 45 months, respectively. We currently have a patient who has not had cancer progression for 3 years and 6 months with monotherapy. Regorafenib and TFTD can potentially improve the survival time beyond our observations on monotherapy when used at the appropriate time and with a thorough understanding of their adverse effects.

      Pubmed     Full text   Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…